Comparison of Progenitor Cell Collection on Day 4 or Day 5 After Steady-State Stimulation with G-CSF Alone in Breast Cancer Patients: Influence on CD34+Cell Yield, Subpopulation, and Breast Cancer Cell Contamination
- 1 February 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 9 (1) , 111-117
- https://doi.org/10.1089/152581600319694
Abstract
To determine the influence of apheresis timing on CD34+ cell yield, subpopulation, and breast cancer cell contamination, 48 women with breast cancer were stimulated from steady-state hematopoiesis in a prospective but nonrandomized study with 2 X 5 mug/kg G-CSF s.c. alone, and apheresis was started either on day 4 (n = 24) or day 5 (n = 24). Forty-eight women with breast cancer (stage II/III, n = 30; stage IV; n = 12; inflammatory, n = 6) and a median age of 44 years were well balanced between the two groups. In group I, aphersis was started on day 4 and additionally performed on day 5 after G-CSF stimulation, and in group II, apheresis was started on day 5. CD34+ cell count and CD34+ cell subpopulation were determined according to international criteria. Breast cancer cell contamination was detected by immunocytology. The median CD34+ cell harvest on day 4 was 3.3 X 106/kg body weight (range 0.5-12.8) and 6 X 106/kg BW (range 0.3-30) for patients starting on day 5 (p = 0.01). Those patients starting on day 4 achieved a median CD34+ cell count of 4 X 106/kg (range 0.7-13) on day 5 (NS). Twenty-one percent of group I and 71% of group II achieved >5 X 106/kg BW CD34+ cells in the first apheresis, whereas 6/kg BW CD34+ cells in the first apheresis were observed in 38% of group I and 16% of group II. No differences were observed between the CD34+ cell subpopulations, CD34+/CD38+ (10.5% versus 10.5%) and CD34+/Thy1+ (1.5% versus 1.8%). The CD34+ cell harvest from consecutive collecting on days 4 and 5 was nearly identical to the harvest starting on day 5 (6.4 versus 6 X 106/kg). Collecting CD34+ progenitor cells after stimulation with G-CSF alone on day 5 results in a significantly higher cell yield than starting collecting on day 4. No differences in respect to breast cancer cell contamination and CD34+ cell subpopulation were observed.Keywords
This publication has 25 references indexed in Scilit:
- Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg)Bone Marrow Transplantation, 1999
- Mobilizing peripheral blood stem cells with high‐dose G‐CSF alone is as effective as with Dexa‐BEAM plus G‐CSF in lymphoma patientsBritish Journal of Haematology, 1998
- Comparison of Molecular Cytokeratin 19 Reverse Transcriptase Polymerase Chain Reaction (CK19 RT-PCR) and Immunocytochemical Detection of Micrometastatic Breast Cancer Cells in Hematopoietic HarvestsJournal of Hematotherapy, 1997
- Factors Influencing Yields of Progenitor Cells for Allogeneic Transplantation: Optimization of G-CSF Dose, Day of Collection, and Duration of LeukapheresisJournal of Hematotherapy, 1997
- Comparison between Bone Marrow and G‐CSF‐Mobilized Peripheral Blood Allografts Undergoing Clinical Scale CD34 + Cell SelectionThe International Journal of Cell Cloning, 1996
- The ISHAGE Guidelines for CD34+ Cell Determination by Flow CytometryJournal of Hematotherapy, 1996
- Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantationBritish Journal of Haematology, 1996
- Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantationBritish Journal of Haematology, 1994
- G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graftBritish Journal of Haematology, 1994
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992